2014

Pharmaceuticals - Scandinavia Industry Guide

NEW YORK, March 26, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - Scandinavia Industry Guide

http://www.reportlinker.com/p0191855/Pharmaceuticals---Scandinavia-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals - Scandinavia Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry in each of the Scandinavian (Denmark, Norway and Sweden) countries. The report includes easily comparable data on market value, segmentation, and five forces analysis, plus full five year market forecasts for each country. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report * Contains an executive summary market values, and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Denmark, Norway and Sweden, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights The Scandinavian pharmaceuticals market had a total market value of $10.0 billion in 2011. Denmark was the fastest growing country with a CAGR of 4.7% over the 2007-11 period.

Within the pharmaceuticals industry, Sweden is the leading country among the Scandinavian countries, with market revenues of $4.7 billion in 2011. Sweden is expected to lead the pharmaceuticals in the Scandinavian countries, with a value of $5.1 billion in 2016.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.

Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).

Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.

TABLE OF CONTENTSIntroduction 8What is this report about? 8Who is the target reader? 8How to use this report 8Definitions 8Scandinavia Pharmaceuticals Industry Outlook 9Pharmaceuticals in Denmark 12Market Overview 12Market Data 13Market Segmentation 14Market outlook 16Five forces analysis 17Macroeconomic indicators 25Pharmaceuticals in Norway 27Market Overview 27Market Data 28Market Segmentation 29Market outlook 31Five forces analysis 32Macroeconomic indicators 40Pharmaceuticals in Sweden 42Market Overview 42Market Data 43Market Segmentation 44Market outlook 46Five forces analysis 47Macroeconomic indicators 55Company Profiles 57Leading companies 57Appendix 89Methodology 89

LIST OF TABLES

Table 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 9

Table 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 10

Table 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 11

Table 4: Denmark pharmaceuticals market value: $ billion, 2007–11 13

Table 5: Denmark pharmaceuticals market geography segmentation: $ billion, 2011 14

Table 6: Denmark pharmaceuticals market share: % share, by value, 2011 15

Table 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 16

Table 8: Denmark size of population (million), 2007–11 25

Table 9: Denmark gdp (constant 2000 prices, $ billion), 2007–11 25

Table 10: Denmark gdp (current prices, $ billion), 2007–11 25

Table 11: Denmark inflation, 2007–11 26

Table 12: Denmark consumer price index (absolute), 2007–11 26

Table 13: Denmark exchange rate, 2007–11 26

Table 14: Norway pharmaceuticals market value: $ billion, 2007–11 28

Table 15: Norway pharmaceuticals market geography segmentation: $ billion, 2011 29

Table 16: Norway pharmaceuticals market share: % share, by value, 2011 30

Table 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 31

Table 18: Norway size of population (million), 2007–11 40

Table 19: Norway gdp (constant 2000 prices, $ billion), 2007–11 40

Table 20: Norway gdp (current prices, $ billion), 2007–11 40

Table 21: Norway inflation, 2007–11 41

Table 22: Norway consumer price index (absolute), 2007–11 41

Table 23: Norway exchange rate, 2007–11 41

Table 24: Sweden pharmaceuticals market value: $ billion, 2007–11 43

Table 25: Sweden pharmaceuticals market geography segmentation: $ billion, 2011 44

Table 26: Sweden pharmaceuticals market share: % share, by value, 2011 45

Table 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 46

Table 28: Sweden size of population (million), 2007–11 55

Table 29: Sweden gdp (constant 2000 prices, $ billion), 2007–11 55

Table 30: Sweden gdp (current prices, $ billion), 2007–11 55

Table 31: Sweden inflation, 2007–11 56

Table 32: Sweden consumer price index (absolute), 2007–11 56

Table 33: Sweden exchange rate, 2007–11 56

Table 34: Pfizer Inc.: key facts 57

Table 35: Pfizer Inc.: key financials ($) 58

Table 36: Pfizer Inc.: key financial ratios 58

Table 37: GlaxoSmithKline Plc: key facts 60

Table 38: GlaxoSmithKline Plc: key financials ($) 61

Table 39: GlaxoSmithKline Plc: key financials (£) 62

Table 40: GlaxoSmithKline Plc: key financial ratios 62

Table 41: Orifarm A/S: key facts 64

Table 42: Pfizer Inc.: key facts 65

Table 43: Pfizer Inc.: key financials ($) 66

Table 44: Pfizer Inc.: key financial ratios 66

Table 45: GlaxoSmithKline Plc: key facts 68

Table 46: GlaxoSmithKline Plc: key financials ($) 69

Table 47: GlaxoSmithKline Plc: key financials (£) 70

Table 48: GlaxoSmithKline Plc: key financial ratios 70

Table 49: AstraZeneca PLC: key facts 72

Table 50: AstraZeneca PLC: key financials ($) 73

Table 51: AstraZeneca PLC: key financial ratios 74

Table 52: Johnson & Johnson: key facts 76

Table 53: Johnson & Johnson: key financials ($) 77

Table 54: Johnson & Johnson: key financial ratios 77

Table 55: Pfizer Inc.: key facts 79

Table 56: Pfizer Inc.: key financials ($) 80

Table 57: Pfizer Inc.: key financial ratios 80

Table 58: AstraZeneca PLC: key facts 82

Table 59: AstraZeneca PLC: key financials ($) 83

Table 60: AstraZeneca PLC: key financial ratios 84

Table 61: Novartis AG: key facts 86

Table 62: Novartis AG: key financials ($) 87

Table 63: Novartis AG: key financial ratios 87

LIST OF FIGURES

Figure 1: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 9Figure 2: Scandinavia pharmaceuticals industry, revenue ($bn), 2007-16 10Figure 3: Scandinavia pharmaceuticals industry forecast, revenue ($bn), 2011-16 11Figure 4: Denmark pharmaceuticals market value: $ billion, 2007–11 13Figure 5: Denmark pharmaceuticals market geography segmentation: % share, by value, 2011 14Figure 6: Denmark pharmaceuticals market share: % share, by value, 2011 15Figure 7: Denmark pharmaceuticals market value forecast: $ billion, 2011–16 16Figure 8: Forces driving competition in the pharmaceuticals market in Denmark, 2011 17Figure 9: Drivers of buyer power in the pharmaceuticals market in Denmark, 2011 18Figure 10: Drivers of supplier power in the pharmaceuticals market in Denmark, 2011 20Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Denmark, 2011 21Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Denmark, 2011 23Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Denmark, 2011 24Figure 14: Norway pharmaceuticals market value: $ billion, 2007–11 28Figure 15: Norway pharmaceuticals market geography segmentation: % share, by value, 2011 29Figure 16: Norway pharmaceuticals market share: % share, by value, 2011 30Figure 17: Norway pharmaceuticals market value forecast: $ billion, 2011–16 31Figure 18: Forces driving competition in the pharmaceuticals market in Norway, 2011 32Figure 19: Drivers of buyer power in the pharmaceuticals market in Norway, 2011 33Figure 20: Drivers of supplier power in the pharmaceuticals market in Norway, 2011 35Figure 21: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Norway, 2011 36Figure 22: Factors influencing the threat of substitutes in the pharmaceuticals market in Norway, 2011 38Figure 23: Drivers of degree of rivalry in the pharmaceuticals market in Norway, 2011 39Figure 24: Sweden pharmaceuticals market value: $ billion, 2007–11 43Figure 25: Sweden pharmaceuticals market geography segmentation: % share, by value, 2011 44Figure 26: Sweden pharmaceuticals market share: % share, by value, 2011 45Figure 27: Sweden pharmaceuticals market value forecast: $ billion, 2011–16 46Figure 28: Forces driving competition in the pharmaceuticals market in Sweden, 2011 47Figure 29: Drivers of buyer power in the pharmaceuticals market in Sweden, 2011 48Figure 30: Drivers of supplier power in the pharmaceuticals market in Sweden, 2011 50Figure 31: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Sweden, 2011 51Figure 32: Factors influencing the threat of substitutes in the pharmaceuticals market in Sweden, 2011 53Figure 33: Drivers of degree of rivalry in the pharmaceuticals market in Sweden, 2011 54Figure 34: Pfizer Inc.: revenues & profitability 59Figure 35: Pfizer Inc.: assets & liabilities 59Figure 36: GlaxoSmithKline Plc: revenues & profitability 62Figure 37: GlaxoSmithKline Plc: assets & liabilities 63Figure 38: Pfizer Inc.: revenues & profitability 67Figure 39: Pfizer Inc.: assets & liabilities 67Figure 40: GlaxoSmithKline Plc: revenues & profitability 70Figure 41: GlaxoSmithKline Plc: assets & liabilities 71Figure 42: AstraZeneca PLC: revenues & profitability 74Figure 43: AstraZeneca PLC: assets & liabilities 75Figure 44: Johnson & Johnson: revenues & profitability 77Figure 45: Johnson & Johnson: assets & liabilities 78Figure 46: Pfizer Inc.: revenues & profitability 81Figure 47: Pfizer Inc.: assets & liabilities 81Figure 48: AstraZeneca PLC: revenues & profitability 84Figure 49: AstraZeneca PLC: assets & liabilities 85Figure 50: Novartis AG: revenues & profitability 88Figure 51: Novartis AG: assets & liabilities 88

To order this report:: Pharmaceuticals - Scandinavia Industry Guide

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.